Globe Newswire (Tue, 10-Feb 9:00 AM ET)
Globe Newswire (Tue, 13-Jan 9:15 AM ET)
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
Globe Newswire (Tue, 6-Jan 9:15 AM ET)
Creative Medical Technology Highlights FDA-Cleared Platforms, Robust IP, and Clinical Trial Momentum
Market Chameleon (Mon, 27-Oct 4:56 AM ET)
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
Creative Medical Technology Holdings trades on the NASDAQ stock market under the symbol CELZ.
As of April 2, 2026, CELZ stock price climbed to $2.05 with 3,741 million shares trading.
CELZ has a beta of 0.55, meaning it tends to be less sensitive to market movements. CELZ has a correlation of 0.02 to the broad based SPY ETF.
CELZ has a market cap of $7.59 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CELZ traded as high as $13.30 and as low as $1.50.
The top ETF exchange traded funds that CELZ belongs to (by Net Assets): VXF.
CELZ has underperformed the market in the last year with a return of -4.0%, while SPY returned +17.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CELZ shares. However, CELZ has outperformed the market in the last 3 month and 2 week periods, returning +4.2% and +9.2%, while SPY returned -3.7% and -0.1%, respectively. This indicates CELZ has been having a stronger performance recently.
CELZ support price is $1.90 and resistance is $2.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CELZ shares will trade within this expected range on the day.
